Noticias y Actividades de SV Health Investors

SV Health Investors tiene presencia directa en 2 países.

Ver el organigrama con sus 39 ejecutivos principales

Biografías más buscadas en SV Health Investors

• Eugene Hill, Chairman of the Board
• Brent Faduski, Chief Financial Officer, Chief Compliance Officer a...
• Greg Madden, Managing Partner, Medical Devices and Healthcare

Recientes movimientos de ejecutivos en SV Health Investors

• A.J. Rossi que ha sido Principal, Healthcare Growth-Buyout, ha ascendido a Partner, Healthcare Growth-Buyout  (noticia publicada el 23 de diciembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en SV Health Investors.

SV Health Investors tiene 1.564 competidores entre los que se incluyen BlackRock (Estados Unidos), Vanguard (Estados Unidos) y Blackstone Group (Estados Unidos).

Popular M&A news in Fondo

• Seven2 has announced the acquisition of HRK Lunis  (publicado el 3 de abril de 2025).
• Fluent ha RIV Capital adquirido (publicado el 20 de diciembre de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado el 14 de octubre de 2024)..

Otros contactos sugeridos en el sector Fondo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer en Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director en Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director en General Catalyst Partners

Saber más sobre el sector Fondo

Últimos comunicados de prensa de SV Health Investors

• News - SV Health Investors
• Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease - SV Health Investors
• British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2 - SV Health Investors
• Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 - SV Health Investors
• Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease - SV Health Investors
• Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board - SV Health Investors
• FDA Approves Expanded Use of Miach Orthopaedics’ BEAR® Implant - SV Health Investors
• QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers - SV Health Investors
• Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer - SV Health Investors
• TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases - SV Health Investors
• View more press releases Close

Redes sociales sobre SV Health Investors

• SV Health Investors en Wikipedia, Google News y Yahoo Finance
• SV Health Investors en LinkedIn, Twitter y YouTube